Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture
View Patent ↗Disclosed are methods of, and assay and kits for, detecting and diagnosing arterial plaque rupture using the expression of miR-222, mi-221 and circ284. Also disclosed are methods of treating arterial plaque rupture and methods of identifying agents for use thin the treatment of arterial plaque rupture.
1. A method comprising:
detecting expression of at least one of micro RNA-221 (miR-221) and miR-222 in a sample obtained from a subject with or believed to have an arterial plaque rupture in an artery;
detecting expression of circular RNA-284 (circR-284) in the sample obtained from the subject;
detecting a ratio of expression levels of circR-284 to at least one of miR-221 and miR-222 greater than a reference value indicative of a no rupture indicating that the subject has experienced arterial plaque rupture; and
administering an effective amount of tissue plasminogen activator (tPA) to the subject having the detected ratio of expression levels greater than the reference value.
2. The method of claim 1 , further comprising, selecting a subject with, or believed to have, suffered a stroke and/or transient ischemic attack (TIA) or a myocardial infarction.
3. The method of claim 1 , wherein the method is used for diagnosing or prognosis of a subject with stroke and/or myocardial infarction.
4. The method of claim 1 , wherein the expression of miR-221, miR-222, and/or circR-284 is detected with a probe and/or primers that respectively specifically bind to miR-221, miR-222, and/or circR-284, or an amplification product thereof, wherein the probe and/or primers are labeled with a detectable label.
5. A method of treating a stroke or myocardial infarction in a subject, comprising:
detecting expression of at least one of micro RNA-221 (miR-221) and miR-222 in a sample from a subject suffering from or believed to have experienced a stroke or myocardial infarction;
detecting expression of circular RNA-284 (circR-284) in a sample obtained from the subject; and
detecting a ratio of expression levels of circR-284 to at least one of miR-221 and miR-222 greater than a reference value indicating that the subject would benefit from treatment with tissue plasminogen activator (tPA); and
administering to the subject having the detected ratio of expression levels greater than the reference value an effective amount of tPA, thereby treating the stroke or myocardial infarction in the subject.
6. The method of claim 5 , further comprising, selecting a subject with, or believed to have, suffered a stroke and/or transient ischemic attack (TIA) or a myocardial infarction.
7. The method of claim 5 , further comprising, comparing the expression of one or more of miR-221, miR-222, or circR-284 to a control.
8. The method of claim 5 , wherein the expression of miR-221, miR-222, and/or circR-284 and/or is detected with a probe and/or primers that specifically bind to miR-221, miR-222, and/or circR-284 and/or, or an amplification product thereof wherein the probe and/or primers are labeled with a detectable label.